Tracker › Companies › Artiva Biotherapeutics, Inc.
3 No sign of it. We found no public evidence tying Artiva Biotherapeutics, Inc.'s cuts to AI.
Every tracked 2026 layoff at Artiva Biotherapeutics, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 3/100 (Minimal) · 80% interval 2–3 · evidence grade D · US · Pharma / Chemicals
Stated reason: On October 22, 2026, the board of directors of the Company approved the discontinuation of the Company’s development of AlloNK ® (AB-101), its non-genetically modified, allogeneic natural killer (NK) cell therapy candidate, as the Company conducts a process to explore strategic alternatives to maximize stockholder value, which includes a plan to implement a reduction of the Company’s workforce by approximately 94% of…
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.761, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · named roles: Computer and Information Systems Managers, General and Operations Managers
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 3,800 workers
Health Care & Pharma · 648 workers
Health Care & Pharma · 419 workers
Health Care & Pharma · 365 workers
Health Care & Pharma · 300 workers
Health Care & Pharma · 120 workers
